Tagged Articles

canagliflozin 35 articles

Man sues Invokana makers over serious blood disorder

Johnson & Johnson subsidiary Janssen Pharmaceuticals is being sued by a Texas man who claims the company’s type 2 diabetes drug Invokana caused him to develop ketoacidosis, a potentially life-threatening condition in which too much acid builds up in the blood. Arthur Portnoff, who filed his lawsuit in Philadelphia Court of Common Pleas, claims he began taking the drug in November 2014 and was hospitalized in February 2015 with ketoacidosis. He claims that Janssen knew the drug could cause serious injuries but failed to adequately warn patients or doctors of this risk. His complaint also states that Janssen did not ... Read More

Invokana linked to ketoacidosis, bone fractures, bone density loss

Drugs from the newest class of type 2 diabetes treatments have been liked to a serious condition called ketoacidosis, in which too much acid builds up in the blood. Ketoacidosis requires immediate medical attention, and if left untreated can lead to diabetic coma or death. The class of drugs are known as sodium-glucose cotransporter-2 (SGLT2) inhibitors and include the brand-name medications Invokana, Invokamet, Farxiga, Xigduo XR, Jardiance, Glyxambi. The first in the class, Invokana, was approved by the Food and Drug Administration (FDA) in 2013. SGLT2 inhibitors prevent high blood sugar by helping the kidneys remove excess sugar through urine. ... Read More

Four Dangerous Diabetes Drugs

Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More

Diabetes drugs including Invokana linked to ketoacidosis

Three type 2 diabetes drugs have been linked to ketoacidosis, a serious metabolic state that can lead to diabetic coma or even death, the Food and Drug Administration (FDA) warned. The drugs include the brand names Invokana (canagliflozin), Farxiga (dapagliflozin) and Jardiance (empagliflozin), which all belong to a class called sodium-glucose co-transporter-2 (SGLT2) inhibitors. At least two studies have found an increased risk of ketoacidosis, or diabetic ketoacidosis (DKA), in patients who take an SGLT2 inhibitor. The warning is based on a search of reports of ketoacidosis reported to the FDA Adverse Event Reporting System, which revealed 20 cases of ... Read More

Combining old diabetes drug with new improves blood sugar control

Combining the commonly used metformin with another class of medication can greatly improve blood sugar control in Type 2 diabetics, according to new research. Metformin is in a class of drugs called biguanides. It works by decreasing the amount of glucose absorbed by food and the amount of glucose made by the liver. By doing this, it increases the body’s response to insulin. It is used alone or with other medications, including insulin, to treat type 2 diabetes. The new study, funded by drug maker Sanofi Aventis, tested metformin in combination with a drug in a new class of type ... Read More

FDA orders post-market studies on newly approved type 2 diabetes drug Jardiance

Jardiance (empagliflozin), a new type 2 diabetes drug, has been granted approval by the U.S. Food and Drug Administration (FDA). The medication can be used alone or added to existing treatment regimens to control blood sugar levels. Jardiance, made by Boehringer Ingelheim, is in a class of drugs called sodium glucose co-transporter 2 (SGLT2) inhibitors. These drugs work by stopping blood sugar from becoming reabsorbed by the kidneys. Thus, more glucose is excreted by the kidneys, which lowers blood sugar levels. Other SGLT2 drugs include Invokana (canagliflozin) and Farxiga (dapagliflozin). The FDA approved Jardiance based on a review of seven ... Read More

European drug regulators approve new type 2 diabetes treatment

European drug regulators have approved Eli Lilly and Boehringer Ingelheim’s new Type 2 diabetes drug epagliflozin, which will be marketed under the brand name Jardiance. The once-daily tablet is designed to reduce blood sugar levels by blocking glucose reabsorption in the kidneys and remove excess glucose through the urine. Unlike other diabetes treatments, Jardiance does not rely on a patient’s insulin levels in order to be effective. Jardiance is in a class of Type 2 diabetes drugs known as sodium glucose co-transporter 2 (SGLT-2) inhibitors. Other drugs in this class include Canagliflozin, which was the first in the class to ... Read More

European Union approves new combination treatment for type 2 diabetes

European Union drug regulators have approved a new combination pill to treat type 2 diabetes. Vokanamet combines the new diabetes drug Invokana with the standard treatment metformin. The new treatment is made by Johnson & Johnson and will be marketed in Europe by Janssen-Cliag International. The active ingredient in Invokana is canagliflozin, which is in a class of diabetes medications known as sodium-glucose co-transporter 2 (SGLT2) inhibitors. These drugs are designed to help reduce blood sugar levels by preventing the reabsorption of glucose from the kidneys back into the blood, and allows glucose to be excreted in the urine. The U.S. ... Read More

New diabetes drug gets positive review from European drug advisors

An advisory committee for the European drug authority is recommending the approval of empagliflozin, a new type 2 diabetes drug made by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is in a new class of diabetes drugs known as sodium glucose co-transporter 2, or SGLT-2, inhibitors. It works by targeting glucose directly and works independently of B-cell function and insulin resistance. The drug produces increased urinary glucose excretion, with a consequent lowering of plasma, glucose levels, and weight loss. If approved, the empagliflozin would be marketed under the name Jardiance. Earlier this month, the U.S. Food and Drug Administration ... Read More

FDA requests more data on diabetes drug candidate combining Invokana with metformin

The Food and Drug Administration (FDA) wants more clinical trial data on Janssen’s new type 2 diabetes treatment that combines the recently approved Invokana (canagliflozin) with the widely used metformin, before it will decide whether to approve the new combination therapy. The agency requested more information comparing the twice-daily combination pill with the once-daily canagliflozin. Janssen, a Johnson & Johnson company, says it has the data the agency needs from its comprehensive Phase 3 clinical development program for the drug. Canagliflozin was approved by the FDA in March 2013. It is the first approved drug in a new class of ... Read More